圣湘生物：子公司完成人生长激素注射液生产药品备案，新增原液生产线

财经网2025-04-15

近日，圣湘生物发布子公司相关产品完成境内生产药品备案的公告。披露中山圣湘海济生物医药有限公司从国家药品监督管理局网站查询获知，公司产品人生长激素注射液于近日完成境内生产药品备案，新增原液生产线。人生长激素注射液于 2023 年 11 月获批上市，适应症为用于因内源性生长激素缺乏而导致的儿童生长缓慢和因 Noonan 综合征所引起的儿童身材矮小，活性成分为人生长激素。产品规格为 30IU/10mg/...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2527172499?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-15 08:55","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2527172499","market":"sh","top_or_hot":-1,"title":"圣湘生物：子公司完成人生长激素注射液生产药品备案，新增原液生产线","media":"财经网","content":"<div>\n<p>近日，圣湘生物发布子公司相关产品完成境内生产药品备案的公告。披露中山圣湘海济生物医药有限公司从国家药品监督管理局网站查询获知，公司产品人生长激素注射液于近日完成境内生产药品备案，新增原液生产线。人生长激素注射液于 2023 年 11 月获批上市，适应症为用于因内源性生长激素缺乏而导致的儿童生长缓慢和因 Noonan 综合征所引起的儿童身材矮小，活性成分为人生长激素。产品规格为 30IU/10mg/...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504150856079737f577&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>圣湘生物：子公司完成人生长激素注射液生产药品备案，新增原液生产线</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n圣湘生物：子公司完成人生长激素注射液生产药品备案，新增原液生产线\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-15 08:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504150856079737f577&s=b><strong>财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，圣湘生物发布子公司相关产品完成境内生产药品备案的公告。披露中山圣湘海济生物医药有限公司从国家药品监督管理局网站查询获知，公司产品人生长激素注射液于近日完成境内生产药品备案，新增原液生产线。人生长激素注射液于 2023 年 11 月获批上市，适应症为用于因内源性生长激素缺乏而导致的儿童生长缓慢和因 Noonan 综合征所引起的儿童身材矮小，活性成分为人生长激素。产品规格为 30IU/10mg/...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504150856079737f577&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688289","symbol_name":"圣湘生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504150856079737f577&s=b","article_id":"2527172499","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504150856079737f577&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2527172499","pubTimestamp":1744678530,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"披露中山圣湘海济生物医药有限公司从国家药品监督管理局网站查询获知，公司产品人生长激素注射液于近日完成境内生产药品备案，新增原液生产线。人生长激素注射液于 2023 年 11 月获批上市，适应症为用于因内源性生长激素缺乏而导致的儿童生长缓慢和因 Noonan 综合征所引起的儿童身材矮小，活性成分为人生长激素。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688289":"圣湘生物","BK0239":"医药制造"},"translate_title":"Shengxiang Bio: The subsidiary completed the registration of human growth hormone injection production drugs and added a new stock solution production line","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688289":1},"content_text":"近日，圣湘生物发布子公司相关产品完成境内生产药品备案的公告。披露中山圣湘海济生物医药有限公司从国家药品监督管理局网站查询获知，公司产品人生长激素注射液于近日完成境内生产药品备案，新增原液生产线。人生长激素注射液于 2023 年 11 月获批上市，适应症为用于因内源性生长激素缺乏而导致的儿童生长缓慢和因 Noonan 综合征所引起的儿童身材矮小，活性成分为人生长激素。产品规格为 30IU/10mg/3ml/瓶，批准文号为国药准字 S20230064。该产品系国内第三个获批的短效水剂产品，凭借稳定的品质和良好的性能，目前已顺利打开市场并逐步放量，在客户端形成了较好的口碑。本次完成生产药品备案后，将在现有生产地址中新增原液生产线，原液总产能实现翻倍增长，可有效缓解现有产能瓶颈，提升生产效率，确保中山海济能够更好地满足日益增长的产品需求，从而为产品的进一步市场拓展提供有力支持。（企业公告）(编辑：林辰)关键字：医药","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2527172499","isCrawlerRequest":true}